EVIDENCE GENERATION

FOCUS AREA WORKING GROUP

The mission of the Evidence Generation Focus Area Working Group (FAWG) is to educate the MAPS membership on contemporary practices for data generation strategies, including the design, implementation, and communication of new evidence, and educate the MAPs membership how real-world (RW) evidence may be utilized to support product value; including labeling changes.

Activities: 

To reach our goals, the Evidence Generation FAWG will execute on two key objectives. First, through educational programs and communications, we will increase understanding of requirements for Evidence Generation in the context of Medical Affairs strategic planning & execution of evidence generation plans. Second, we will explore applications of real-world evidence across stakeholders within Medical Affairs, with the purpose of increasing the acceptance of real-world evidence for regulatory purposes.

As part of this plan, we will organize a host of Evidence Generation activities including workshops for MAPS meetings in the North America, with longer term plans and aspirations of conducting Evidence Generation workshops in APAC (Asia Pacific – China/Japan), and EMEA (Europe, Middle East, Asia) regions.

We will develop original content for webinars, podcasts, eLearning courses, and white papers. In addition, the working group will periodically contribute cogent and timely content on the Evidence Generation sector for the MAPS publication, Elevate magazine. Most importantly, we will provide a supportive resource for all Medical Affairs professionals seeking advice and direction on data generation and regulatory strategies.

Strategic Objectives

  1. Enhance foundational knowledge, standards and technical skills for evidence generation:
    • Develop understanding of standards and guidance for evidence generation.
    • Support planning & execution of evidence generation strategy in Medical Affairs.
  2. Increase opportunities for evidence generation:
    • Explore applications of real-world evidence across Regions.
    • Increase transparency and acceptance of real-world evidence.

LATEST PODCAST EPISODE

Description: MAPS speaks with Kent Summers, HEOR Lead at AlphaGroup and Steve Camper, VP of Medical Affairs at Blue Earth Diagnostics, about building Health Economics and Outcomes Research capabilities within Medical Affairs.

FAWG OVERVIEW

MEMBERS

RESOURCES RELATED TO EVIDENCE GENERATION

Activating health equity: The vital role of Medical Affairs

Medical Affairs is in the unique position to drive health equity through three main roles: catalyser, capabilities enhancer, and cross-functional collaborator, emphasizing the need for deliberate strategies and actions to close health gaps and improve outcomes for underserved populations.
Implementation Science Featured

Implementation Science: A Catalyst for Advancing Healthcare

This introduction to implementation science offers Medical Affairs professionals a 4-step scientific approach for accelerating the adoption of evidence-based care into practice.
Real World Evidence Applications and How it Can Change Medicine and Biopharma

Real World Evidence Applications and How it Can Change Medicine and Biopharma

This podcast focuses on applications of Real World Evidence including FDA criteria for accepting RWE, types of data, RWE study designs and the Totality of Evidence approach.
Field Medical External Stakeholders: Partnering for Today and Tomorrow - episode 2 Partnering with Patient Advocacy Organizations

Field Medical External Stakeholders: Episode 2 Partnering with Patient Advocacy Organizations

This MAPS podcast details potential areas for compliant collaboration by MSLs with Patient Advocacy Groups.

How to Engage External Research (IIR and Collaborative Research) – Practical Compliance Considerations

This webinar explores WHAT is IIR vs. Collaborative Research and discusses the challenges of conducting IIR and Collaborative Research.
Evidence Generation Medical Affairs Podcast 3

Impact of the 21st Century Cures Act

The objective of this podcast is to discuss how the 21st Century Cures Act has led to new initiatives at FDA involving Real World Evidence.